Skip to main content

Table 2 Changes in disease activity and the proportion of monocyte subsets in patients with rheumatoid arthritis (n = 35) at baseline and following 12 weeks of methotrexate treatment

From: CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis

  Baseline 12 weeks p value
Disease activity parameters
 DAS28-ESR 4.83 ± 0.91 3.53 ± 1.25 <0.001
 SDAI 18.99 ± 9.87 10.24 ± 7.77 <0.001
 CDAI 18.35 ± 9.03 9.84 ± 7.55 <0.001
 ESR 35.7 ± 20.0 27.2 ± 23.4 0.0040
 CRP 0.64 ± 0.59 0.35 ± 0.59 0.031
Monocyte subsets
 CD14brightCD16- monocytes (%) 72.16 ± 9.87 77.57 ± 9.36 0.0042
 CD14brightCD16+ monocytes (%) 13.96 ± 7.02 10.89 ± 7.25 0.0019
 CD14dimCD16+ monocytes (%) 8.14 ± 4.84 6.41 ± 4.20 0.0619
  1. Statistical analysis, Wilcoxon rank sum test. DAS-28 disease activity score in 28-joint count, SDAI simplified disease activity index, CDAI clinical disease activity index, ESR erythrocyte sedimentation rate, CRP C-reactive protein.